➤ Get the DrugPatentWatch Daily Briefing

Get Daily Updates on Generic Entry, Litigation, Biosimilars, and more …

Serving leading biopharmaceutical companies globally:

McKesson
Dow
Moodys
Medtronic
Merck
AstraZeneca

Last Updated: July 6, 2020

DrugPatentWatch Database Preview

SULFACETAMIDE SODIUM Drug Profile


Email this page to a colleague

» See Plans and Pricing

« Back to Dashboard

When do Sulfacetamide Sodium patents expire, and when can generic versions of Sulfacetamide Sodium launch?

Sulfacetamide Sodium is a drug marketed by Fougera Pharms, Perrigo Co Tennessee, Taro, Akorn, Alcon Pharms Ltd, Bausch And Lomb, Pharmafair, and Sandoz Inc. and is included in twelve NDAs.

The generic ingredient in SULFACETAMIDE SODIUM is prednisolone sodium phosphate; sulfacetamide sodium. There are eighty-eight drug master file entries for this compound. Three suppliers are listed for this compound. Additional details are available on the prednisolone sodium phosphate; sulfacetamide sodium profile page.

Drug patent expirations by year for SULFACETAMIDE SODIUM
Recent Clinical Trials for SULFACETAMIDE SODIUM

Identify potential brand extensions & 505(b)(2) entrants

SponsorPhase
Sidney Kimmel Cancer Center at Thomas Jefferson UniversityN/A

See all SULFACETAMIDE SODIUM clinical trials

Pharmacology for SULFACETAMIDE SODIUM
Medical Subject Heading (MeSH) Categories for SULFACETAMIDE SODIUM

US Patents and Regulatory Information for SULFACETAMIDE SODIUM

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Fougera Pharms SULFACETAMIDE SODIUM sulfacetamide sodium LOTION;TOPICAL 077015-001 Nov 17, 2006 AB RX No No   Start Trial   Start Trial   Start Trial
Alcon Pharms Ltd SULFACETAMIDE SODIUM sulfacetamide sodium SOLUTION/DROPS;OPHTHALMIC 089068-001 May 5, 1987 DISCN No No   Start Trial   Start Trial   Start Trial
Perrigo Co Tennessee SULFACETAMIDE SODIUM sulfacetamide sodium OINTMENT;OPHTHALMIC 080029-001 Approved Prior to Jan 1, 1982 RX No Yes   Start Trial   Start Trial   Start Trial
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Exclusivity Expiration

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

McKesson
Dow
Moodys
Medtronic
Merck
AstraZeneca

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.